JLR/2013/041541 1 In vivo effects of anacetrapib on pre-beta HDL: evidence for improvement in HDL remodeling without effects on cholesterol absorption Sheng-Ping Wang, Erin Daniels, Ying Chen, Jose Castro-Perez, Haihong Zhou, Karen O. Akinsanya, Stephen F. Previs, Thomas P. Roddy, Douglas G. Johns Department of Atherosclerosis, Merck Research Laboratories, Rahway NJ, USA 07065 To whom correspondence should be addressed: Douglas G. Johns, PhD, FAHA Merck Research Laboratories Department of Atherosclerosis 126 E. Lincoln Ave RY80T-A185 Rahway NJ, 07065 732-594-3231 Douglas_Johns@merck.com by guest, on July 28, 2016 www.jlr.org Downloaded from